REVIEW article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1609712
Title：Potential Application of Nanodelivery Systems Targeting ELAVL1 in Prostate Cancer
Provisionally accepted
Sha sha Min1Guo meng meng2Chen jiao Hunag1Du jia Nuo1Shen yan Ting2Yuan fu wen2Wang zhong1
Zhonglin Cai2*- 1University of Shanghai for Science and Technology, Shanghai, Shanghai Municipality, China
- 2Department of Urology, Shanghai Pudong New Area People's Hospital, Pudong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Introduction: Prostate cancer (PCa) is one of the most common malignant tumors in men, with increasing incidence and mortality rates, and its treatment still faces many challenges and unmet needs. ELAVL1 (human antigen R, HuR) is an RNA-binding protein that plays a crucial role in the development and progression of various cancers. Studies have shown that ELAVL1 is highly expressed in PCa and that inhibiting its expression its expression significantly reduces prostate cell proliferation and metastasis. However, the clinical application of ELAVL1-targeting therapies remains limited by the lack of effective delivery strategies. In this context, recent advances in nanodelivery systems offer promising solutions, providing both enhanced targeting efficiency and insights for future prostate cancer treatment strategies. Objective: This review aims to explore the potential of ELAVL1-targeted therapy based on nanodelivery systems in PCa, analyze its advantages and challenges, and provide insights into future research directions. Methods: A systematic review of recent literature summarizing the expression characteristics and biological functions of ELAVL1 in PCa was conducted. Additionally, the advantages, challenges, and applications of various nanomaterials in cancer therapy are discussed. Results: Nanodelivery systems have shown significant potential in the treatment of prostate cancer. Keywords: prostate cancer; nanodelivery system; ELAVL1 (HuR); siRNA
Keywords: prostate cancer, Nanodelivery system, ELAVL1 (HuR), siRNA, Cancer
Received: 10 Apr 2025; Accepted: 31 Jul 2025.
Copyright: © 2025 Min, meng, Hunag, Nuo, Ting, wen, zhong and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhonglin Cai, Department of Urology, Shanghai Pudong New Area People's Hospital, Pudong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.